NCT01605773View on ClinicalTrials.gov

Effect of Repaglinide on Postprandial Lipemia in Type 2 Diabetes

PHASE4CompletedINTERVENTIONAL

Enrollment

51

Participants

Timeline

Start Date

November 8, 2001

Primary Completion Date

March 13, 2003

Study Completion Date

March 13, 2003

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

DRUG

repaglinide

Dose individually adjusted and conducted according to labeling

DRUG

glyburide

Dose individually adjusted and conducted according to labeling

Trial Locations (1)

77030

Novo Nordisk Investigational Site, Houston

Sponsors

Lead Sponsor

Novo Nordisk A/S

All Listed Sponsors

lead

Novo Nordisk A/S

INDUSTRY